Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
J Invest Dermatol ; 144(2): 387-397.e11, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37619833

ABSTRACT

Diabetic chronic ulcers are plagued with persistent nonresolving inflammation. However, diabetic wound environment early after injury suffers from inadequate inflammatory responses due to reductions in proinflammatory cytokines levels. Diabetic neutrophils have known impairments in bactericidal functions. We hypothesized that reduced bacterial killing by diabetic neutrophils, due to their bactericidal functional impairments, results in reduced bioactive bacterial products, known as pathogen-associated molecular patterns, which in turn contribute to reduced signaling through toll-like receptors, leading to inadequate production of proinflammatory cytokines in infected diabetic wound early after injury. We tested our hypothesis in db/db type 2 obese diabetic mouse wound infection model with Pseudomonas aeruginosa. Our data indicate that despite substantially higher levels of infection, toll-like receptor 4-mediated signaling is reduced in diabetic wounds early after injury owing to reduced bioactive levels of lipopolysaccharide. We further demonstrate that topical treatment with lipopolysaccharide enhances toll-like receptor 4 signaling, increases proinflammatory cytokine production, restores leukocyte trafficking, reduces infection burden, and stimulates healing in diabetic wounds. We posit that lipopolysaccharide may be a viable therapeutic option for the treatment of diabetic foot ulcers if it is applied topically after the surgical debridement process, which is intended to reset chronic ulcers into acute fresh wounds.


Subject(s)
Diabetes Mellitus, Type 2 , Diabetic Foot , Wound Infection , Mice , Animals , Toll-Like Receptor 4 , Pathogen-Associated Molecular Pattern Molecules/therapeutic use , Lipopolysaccharides , Wound Infection/drug therapy , Diabetic Foot/drug therapy , Anti-Bacterial Agents/therapeutic use , Immunity , Cytokines
2.
J Am Chem Soc ; 145(48): 26296-26307, 2023 12 06.
Article in English | MEDLINE | ID: mdl-37987621

ABSTRACT

Immunotherapy of triple-negative breast cancer (TNBC) has an unsatisfactory therapeutic outcome due to an immunologically "cold" microenvironment. Fusobacterium nucleatum (F. nucleatum) was found to be colonized in triple-negative breast tumors and was responsible for the immunosuppressive tumor microenvironment and tumor metastasis. Herein, we constructed a bacteria-derived outer membrane vesicle (OMV)-coated nanoplatform that precisely targeted tumor tissues for dual killing of F. nucleatum and cancer cells, thus transforming intratumor bacteria into immunopotentiators in immunotherapy of TNBC. The as-prepared nanoparticles efficiently induced immunogenic cell death through a Fenton-like reaction, resulting in enhanced immunogenicity. Meanwhile, intratumoral F. nucleatum was killed by metronidazole, resulting in the release of pathogen-associated molecular patterns (PAMPs). PAMPs cooperated with OMVs further facilitated the maturation of dendritic cells and subsequent T-cell infiltration. As a result, the "kill two birds with one stone" strategy warmed up the cold tumor environment, maximized the antitumor immune response, and achieved efficient therapy of TNBC as well as metastasis prevention. Overall, this strategy based on a microecology distinction in tumor and normal tissue as well as microbiome-induced reversal of cold tumors provides new insight into the precise and efficient immune therapy of TNBC.


Subject(s)
Triple Negative Breast Neoplasms , Humans , Triple Negative Breast Neoplasms/metabolism , Adjuvants, Immunologic , Pathogen-Associated Molecular Pattern Molecules/metabolism , Pathogen-Associated Molecular Pattern Molecules/therapeutic use , Immunotherapy/methods , Fusobacterium nucleatum/metabolism , Cell Line, Tumor , Tumor Microenvironment
3.
Urol Clin North Am ; 47(4S): e1-e8, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33446322

ABSTRACT

Relatively simple, synthetic, double-stranded RNAs can be powerful viral pathogen-associated molecular pattern (PAMP) mimics, inducing a panoply of antiviral and antitumor responses that act at multiple stages of host defense. Their mechanisms of action and uses are beginning to be understood, alone, in combination with other therapeutics, or as novel PAMP-adjuvants providing the critical danger signal that has been missing from most cancer and other modern vaccines. Dose, timing, route of administration combinations, and other clinical variables can have a critical impact on immunogenicity. This article reviews advances in the use of polyinosinic-polycytidylic acid and derivatives, in particular poly-ICLC.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Carboxymethylcellulose Sodium/analogs & derivatives , Immunologic Factors/therapeutic use , Poly I-C/therapeutic use , Polylysine/analogs & derivatives , Prostatic Neoplasms/therapy , RNA, Double-Stranded/therapeutic use , Adjuvants, Immunologic/physiology , Cancer Vaccines/immunology , Cancer Vaccines/therapeutic use , Carboxymethylcellulose Sodium/therapeutic use , Clinical Trials as Topic , Humans , Immunologic Factors/immunology , Male , Pathogen-Associated Molecular Pattern Molecules/immunology , Pathogen-Associated Molecular Pattern Molecules/therapeutic use , Poly I-C/immunology , Polylysine/immunology , Polylysine/therapeutic use , Prostatic Neoplasms/immunology , RNA, Double-Stranded/immunology
SELECTION OF CITATIONS
SEARCH DETAIL